Standout Papers

<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas 2007 2026 2013 2019 4.2k
  1. IDH1andIDH2Mutations in Gliomas (2009)
    Hai Yan, D. Williams Parsons et al. New England Journal of Medicine
  2. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group (2010)
    Patrick Y. Wen, David R. Macdonald et al. Journal of Clinical Oncology
  3. Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme (2007)
    James J. Vredenburgh, Annick Desjardins et al. Journal of Clinical Oncology
  4. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma (2020)
    David A. Reardon, Alba A. Brandes et al. JAMA Oncology
  5. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma (2007)
    James J. Vredenburgh, Annick Desjardins et al. Clinical Cancer Research
  6. Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma (2010)
    John H. Sampson, Amy B. Heimberger et al. Journal of Clinical Oncology
  7. Phase II Trial of Gefitinib in Recurrent Glioblastoma (2003)
    Jeremy N. Rich, David A. Reardon et al. Journal of Clinical Oncology
  8. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group (2015)
    Hideho Okada, Michael Weller et al. The Lancet Oncology
  9. Molecular targeted therapy of glioblastoma (2019)
    Émilie Le Rhun, Matthias Preusser et al. Cancer Treatment Reviews
  10. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 (2017)
    Antonio Omuro, Gordana Vlahovic et al. Neuro-Oncology
  11. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study (2015)
    James M. Schuster, Lawrence D. Recht et al. Neuro-Oncology

Immediate Impact

14 by Nobel laureates 56 from Science/Nature 194 standout
Sub-graph 1 of 18

Citing Papers

mRNA-based therapeutics: looking beyond COVID-19 vaccines
2024 StandoutNobel
Glioblastoma and Other Primary Brain Malignancies in Adults
2023 Standout
23 intermediate papers

Works of David A. Reardon being referenced

Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade
2018
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series
2012
and 34 more

Author Peers

Author Last Decade Papers Cites
David A. Reardon 20314 8565 7151 10207 552 33.1k
Henry S. Friedman 21140 8859 7759 14778 564 37.6k
Timothy F. Cloughesy 19925 6199 6327 10680 553 32.8k
Alba A. Brandes 23019 6491 9461 9884 356 33.2k
Jill S. Barnholtz‐Sloan 18897 6891 9065 11383 433 39.7k
Patrick Y. Wen 23253 9683 11228 12006 775 41.8k
Warren Mason 20059 5614 7489 10386 213 32.4k
Roger E. McLendon 18272 12748 5204 19151 325 41.0k
Michael D. Prados 18387 4843 7284 7766 407 27.0k
Mark R. Gilbert 14723 5722 6592 6398 482 24.1k
Roger Stupp 30511 9311 13661 15389 373 48.5k

All Works

Loading papers...

Rankless by CCL
2026